JP2018527011A5 - - Google Patents

Download PDF

Info

Publication number
JP2018527011A5
JP2018527011A5 JP2018514889A JP2018514889A JP2018527011A5 JP 2018527011 A5 JP2018527011 A5 JP 2018527011A5 JP 2018514889 A JP2018514889 A JP 2018514889A JP 2018514889 A JP2018514889 A JP 2018514889A JP 2018527011 A5 JP2018527011 A5 JP 2018527011A5
Authority
JP
Japan
Prior art keywords
disease
syndrome
autoimmune
specific
antagonist polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018514889A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018527011A (ja
JP6800219B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2016/071759 external-priority patent/WO2017046200A1/en
Publication of JP2018527011A publication Critical patent/JP2018527011A/ja
Publication of JP2018527011A5 publication Critical patent/JP2018527011A5/ja
Application granted granted Critical
Publication of JP6800219B2 publication Critical patent/JP6800219B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018514889A 2015-09-16 2016-09-15 特異的なインターロイキン−15(il−15)アンタゴニストポリペプチド並びに炎症疾患及び自己免疫疾患の処置のためのその使用 Expired - Fee Related JP6800219B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15306418 2015-09-16
EP15306418.3 2015-09-16
PCT/EP2016/071759 WO2017046200A1 (en) 2015-09-16 2016-09-15 Specific interleukin-15 (il-15) antagonist polypeptide and uses thereof for the treatment of inflammatory and auto-immune diseases

Publications (3)

Publication Number Publication Date
JP2018527011A JP2018527011A (ja) 2018-09-20
JP2018527011A5 true JP2018527011A5 (cg-RX-API-DMAC10.html) 2019-07-18
JP6800219B2 JP6800219B2 (ja) 2020-12-16

Family

ID=54252214

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018514889A Expired - Fee Related JP6800219B2 (ja) 2015-09-16 2016-09-15 特異的なインターロイキン−15(il−15)アンタゴニストポリペプチド並びに炎症疾患及び自己免疫疾患の処置のためのその使用

Country Status (4)

Country Link
US (1) US10858452B2 (cg-RX-API-DMAC10.html)
EP (1) EP3350205A1 (cg-RX-API-DMAC10.html)
JP (1) JP6800219B2 (cg-RX-API-DMAC10.html)
WO (1) WO2017046200A1 (cg-RX-API-DMAC10.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2824515C (en) 2011-01-18 2022-09-13 Bioniz, Llc Compositions and methods for modulating gamma-c-cytokine activity
US9959384B2 (en) 2013-12-10 2018-05-01 Bioniz, Llc Methods of developing selective peptide antagonists
EP3978512A1 (en) 2015-10-09 2022-04-06 Bioniz, LLC Modulating gamma-c-cytokine activity
CA3024509A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Mrna combination therapy for the treatment of cancer
CN109715196A (zh) 2016-06-13 2019-05-03 转矩医疗股份有限公司 用于促进免疫细胞功能的组合物和方法
KR102707650B1 (ko) 2017-04-07 2024-09-19 바이오니즈 테라퓨틱스, 아이엔씨. 감마-c-사이토카인 활성의 안정한 조절자
AU2018257917B2 (en) * 2017-04-24 2023-05-04 University Of Massachusetts Diagnosis and treatment of vitiligo
CA3074826A1 (en) 2017-09-05 2019-03-14 Torque Therapeutics, Inc. Therapeutic protein compositions and methods of making and using the same
CN121086085A (zh) * 2018-06-22 2025-12-09 科优基因公司 新型白介素-15 (il-15)融合蛋白及其用途
WO2020023702A1 (en) 2018-07-25 2020-01-30 AskGene Pharma, Inc. Novel il-21 prodrugs and methods of use thereof
BR112021021878A2 (pt) 2019-05-03 2022-01-18 Bioniz Llc Modulação dos efeitos de sinalização da gama-c-citocina para tratamento da alopecia e distúrbios associados
SG11202111409YA (en) 2019-05-20 2021-12-30 Cytune Pharma IL-2/IL-15Rßy AGONIST DOSING REGIMENS FOR TREATING CANCER OR INFECTIOUS DISEASES
CN114341189A (zh) 2019-06-12 2022-04-12 奥美药业有限公司 全新il-15前药及其应用
EP4061146A4 (en) * 2019-07-03 2024-03-20 University of Houston System IL-15 INHIBITORS AND THEIR USE IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY CONDITIONS
KR20220114063A (ko) * 2019-12-13 2022-08-17 큐진 인크. 신규한 인터루킨-15 (il-15) 융합 단백질 및 이의 용도
AU2021205981A1 (en) 2020-01-11 2022-07-14 AskGene Pharma, Inc. Novel masked cytokines and methods of use thereof
KR20230096047A (ko) 2020-10-26 2023-06-29 싸이튠 파마 비흑색종 피부암 치료용 IL-2/IL-15Rβγ 작용제
WO2022090203A1 (en) 2020-10-26 2022-05-05 Cytune Pharma IL-2/IL-15Rβү AGONIST FOR TREATING SQUAMOUS CELL CARCINOMA
JP2024526080A (ja) 2021-06-23 2024-07-17 サイチューン ファーマ インターロイキン15多様体
US20240350589A1 (en) 2021-08-13 2024-10-24 Cytune Pharma Il-2/il-15rbetagamma agonist combination with antibody-drug conjugates for treating cancer
US20230151095A1 (en) 2021-11-12 2023-05-18 Xencor, Inc. Bispecific antibodies that bind to b7h3 and nkg2d
WO2024102636A1 (en) 2022-11-07 2024-05-16 Xencor, Inc. Bispecific antibodies that bind to b7h3 and mica/b
KR20250135294A (ko) * 2023-02-21 2025-09-12 레메젠 코, 리미티드 암을 위한 il-15 작용제
EP4694916A1 (en) 2023-04-14 2026-02-18 SOTIO Biotech Inc. Engineered immune cells for treating cancer in combination with il-2/il-15 receptor ?? agonists
WO2024215987A1 (en) 2023-04-14 2024-10-17 Sotio Biotech Inc. IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-15/IL-15Rα CONJUGATES
WO2025085672A1 (en) 2023-10-17 2025-04-24 Xencor, Inc. Bispecific antibodies that bind to nkp46 and mica/b
WO2025184411A1 (en) 2024-02-27 2025-09-04 Calidi Biotherapeutics (Nevada), Inc. Serum-resistant eev viruses and uses thereof
WO2026107113A1 (en) 2024-11-12 2026-05-21 Calidi Biotherapeutics (Nevada), Inc. MODIFIED CELLS FOR PROGRAMMING EXTRA ENVELOPED VIRUSES (EEVs) AND THEIR USE FOR PRODUCING THE EEVs, THE PROGRAMMED EEVs AND USES THEREOF

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
US5073627A (en) 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
US5108910A (en) 1989-08-22 1992-04-28 Immunex Corporation DNA sequences encoding fusion proteins comprising GM-CSF and IL-3
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
JP3866760B2 (ja) 1993-02-22 2007-01-10 ザ ロックフェラー ユニバーシティ 一過性トランスフェクションによる高力価のヘルパーフリーのレトロウイルスの生産
FR2712812B1 (fr) 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition pour la production de produits thérapeutiques in vivo.
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US20060057680A1 (en) 2004-08-11 2006-03-16 Zheng Xin X Mutant interleukin-15 polypeptides
EP1777294A1 (en) * 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
EP2388266B1 (en) 2007-05-11 2014-04-23 Altor BioScience Corporation Fusion molecules and IL-15 variants
EP2537933A1 (en) * 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
JP2016518361A (ja) * 2013-04-19 2016-06-23 シーチューヌ ファルマCytune Pharma 血管漏出症候群の発生を抑制するサイトカイン治療
CA2920539C (en) 2013-08-08 2024-01-02 Cytune Pharma Combined pharmaceutical composition
SI3030575T1 (sl) 2013-08-08 2018-11-30 Cytune Pharma Modulokini na osnovi IL-15 in IL-15R-alfa sushi domene
EP2915569A1 (en) * 2014-03-03 2015-09-09 Cytune Pharma IL-15/IL-15Ralpha based conjugates purification method

Similar Documents

Publication Publication Date Title
US10858452B2 (en) Specific interleukin-15 (IL-15) antagonist polypeptide and uses thereof for the treatment of inflammatory and auto-immune diseases
JP7641121B2 (ja) ネクチン-4に対して特異的な二環式ペプチドリガンド
JP2020517635A5 (cg-RX-API-DMAC10.html)
JP2013540102A5 (cg-RX-API-DMAC10.html)
JP2018519834A5 (cg-RX-API-DMAC10.html)
JP2014532649A5 (cg-RX-API-DMAC10.html)
HRP20240996T1 (hr) Prefuzija rsv f proteina i njihova uporaba
HRP20230452T1 (hr) Modulatori piruvat kinaze i njihova uporaba
JP2022513025A5 (cg-RX-API-DMAC10.html)
JP2017520569A5 (cg-RX-API-DMAC10.html)
FI3250610T3 (fi) Fcrn-vasta-aineita ja menetelmiä niiden käyttämiseksi
JP2020521751A5 (cg-RX-API-DMAC10.html)
CA2972014A1 (en) Fused pyrimidine compounds for the treatment of hiv
JP2009527499A5 (cg-RX-API-DMAC10.html)
JP2005501514A5 (cg-RX-API-DMAC10.html)
JP2024531259A5 (cg-RX-API-DMAC10.html)
CA3165855A1 (en) Mutant rsv f protein and use thereof
PT2445497T (pt) Utilização de derivados de indoles para o tratamento de cancro
JP2013536174A5 (cg-RX-API-DMAC10.html)
JP2016513471A5 (cg-RX-API-DMAC10.html)
CA2991363A1 (en) Fusion proteins which bind to human fc receptors
JP2013535445A5 (cg-RX-API-DMAC10.html)
JP2015519359A5 (cg-RX-API-DMAC10.html)
US20260083671A1 (en) Stabilized formulation comprising recombinant stabilized galectin 9 protein
JP2022533096A5 (cg-RX-API-DMAC10.html)